Rapid Syndrome Validation

Sandia National Laboratories' Rapid Syndrome Validation Project is a Web-based early warning system designed to detect incoming bioterrorism threats as well as natural disease outbreaks.

The system enables physicians to report clinical information via a touch screen computer. The information is reported in terms of syndromes — such as influenza-like illness or fever with rash — that can indicate bioterrorism infection or a seasonal epidemic. RSVP can analyze the syndrome reports and clinical data against expected baselines. Thus, the system can flag changes that may indicate a bioterrorist attack, according to Sandia officials.

Reports fitting certain disease patterns are dispatched to state public health offices. But RSVP also keeps physicians in the loop, providing a geographic plot of syndrome reports. Alan Zelicoff, a senior scientist at Sandia's Center for National Security and Arms Control, said RSVP's users include the governments of Las Cruces, N.M., San Mateo County, Calif., and Brownsville, Texas. A large deployment is scheduled in Singapore.

Sandia offers the Java-based RSVP for free and will host the software. "Most public health departments don't want to maintain a server," Zelicoff said.

Featured

  • Defense
    Ryan D. McCarthy being sworn in as Army Secretary Oct. 10, 2019. (Photo credit: Sgt. Dana Clarke/U.S. Army)

    Army wants to spend nearly $1B on cloud, data by 2025

    Army Secretary Ryan McCarthy said lack of funding or a potential delay in the JEDI cloud bid "strikes to the heart of our concern."

  • Congress
    Rep. Jim Langevin (D-R.I.) at the Hack the Capitol conference Sept. 20, 2018

    Jim Langevin's view from the Hill

    As chairman of of the Intelligence and Emerging Threats and Capabilities subcommittee of the House Armed Services Committe and a member of the House Homeland Security Committee, Rhode Island Democrat Jim Langevin is one of the most influential voices on cybersecurity in Congress.

Stay Connected

FCW INSIDER

Sign up for our newsletter.

I agree to this site's Privacy Policy.